| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/03/2007 | US7198787 Preferentially kill mammary gland cancer cells; obtain cells, exposed to mixture of toxins, monitor cellular response to toxins |
| 04/03/2007 | US7198779 Compositions for the relief of xerostomia and the treatment of associated disorders |
| 04/03/2007 | CA2425539C Crystalline monohydrate, processes for the preparation thereof and the use thereof for preparing a pharmaceutical composition |
| 04/03/2007 | CA2419573C Method of increasing testosterone and related steroid concentrations in women |
| 04/03/2007 | CA2400945C Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof |
| 04/03/2007 | CA2388452C Oxa- and thiazole derivatives useful as antidiabetic and antiobesity agents |
| 04/03/2007 | CA2385890C Controlled release compositions comprising nimesulide |
| 04/03/2007 | CA2344053C Composition containing cinnamic acid derivatives for preventing or treating elevated blood lipid level-related diseases |
| 04/03/2007 | CA2334904C Method and system for production and collection of lavage induced stool (lis) for chemical and biologic tests of cells |
| 04/03/2007 | CA2328447C Adeno-associated virus vectors and uses thereof |
| 04/03/2007 | CA2309350C Purine derivatives and medicaments comprising the same as active ingredient |
| 04/03/2007 | CA2296586C New 2,3-benzodiazepine derivatives |
| 04/03/2007 | CA2294581C Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl derivatives |
| 04/03/2007 | CA2289570C 9-azabicyclo(3.3.1)non-2-ene and nonane derivatives as cholinergic ligands at nicotinic ach receptors |
| 04/03/2007 | CA2288140C Farnesyltransferase inhibiting quinazolinones |
| 04/03/2007 | CA2281918C Oxazolidines as 5-ht2a-antagonists |
| 04/03/2007 | CA2276459C Novel method for testing the differentiation status in pancreatic cells of a mammal |
| 04/03/2007 | CA2272343C Pharmaceutical compositions containing 3-iodo-1,2-propanediol having mucolytic activity |
| 04/03/2007 | CA2238295C Complementary adenoviral vector systems and cell lines |
| 04/03/2007 | CA2236269C Selective .beta.3 adrenergic agonists |
| 04/03/2007 | CA2210152C Green porphyrins as immunomodulators |
| 04/03/2007 | CA2205275C Vitamin d3 analogs |
| 04/03/2007 | CA2201096C Solid dispersion and solid dispersion dosage form of xanthine derivative |
| 04/03/2007 | CA2198704C Sprayable, film-forming system releasing active substances for use on plants |
| 04/03/2007 | CA2193365C Polynucleotide vaccine for papillomavirus |
| 04/03/2007 | CA2192822C Use of immunosuppressive agents for the treatment of schizophrenia |
| 04/03/2007 | CA2186601C New combination of a .beta.-receptor blocker and a local anaesthetic |
| 04/03/2007 | CA2181006C N,n-diethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine dimaleate |
| 04/03/2007 | CA2180660C Novel piperidine derivatives with paf antagonist activity |
| 04/03/2007 | CA2177578C Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors |
| 04/03/2007 | CA2176510C Method for preparing concentrated biologically active silicon compounds |
| 04/03/2007 | CA2163174C Hindered aromatic ester compounds useful as anti-viral agents |
| 04/03/2007 | CA2160853C Injectable liquid copolymers for soft tissue repair and augmentation |
| 04/03/2007 | CA2149044C Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists |
| 04/03/2007 | CA2107914C Method to profile and treat abnormal cells |
| 04/03/2007 | CA2066384C Gastrointestinal mucosa-adherent matrixes, pharmaceutical preparation and a coating composition |
| 04/03/2007 | CA2065603C Stabilized vitamin d preparation |
| 03/29/2007 | WO2007035964A2 Vigabatrin bioisoteres and related methods of use |
| 03/29/2007 | WO2007035963A2 Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors |
| 03/29/2007 | WO2007035961A2 Anti-cancer therapies |
| 03/29/2007 | WO2007035957A2 Methods for treating viral infections using polyamine analogs |
| 03/29/2007 | WO2007035953A2 Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
| 03/29/2007 | WO2007035945A1 Tetrahydro-cyclopentyl pyrazole cannabinoid modulators |
| 03/29/2007 | WO2007035927A2 Isoflavonoid analogs and their metal conjugates as anti-cancer agents |
| 03/29/2007 | WO2007035879A2 Combination s-nitrosothiol-based pharmaceutical products for restoring normal breathing rhythm |
| 03/29/2007 | WO2007035874A1 Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof |
| 03/29/2007 | WO2007035873A1 Purinone derivatives for treating neurodegenerative diseases |
| 03/29/2007 | WO2007035841A1 Analogs of dehydrophenylahistins and their therapeutic use |
| 03/29/2007 | WO2007035828A2 Compositions and methods for preventing or treating encephalitis with interferon |
| 03/29/2007 | WO2007035823A2 Partial mglur5 antagonists and methods of use thereof |
| 03/29/2007 | WO2007035816A2 Paroxetine compositions |
| 03/29/2007 | WO2007035784A1 Vitamin d derivatives for the treatment of type i diabetes |
| 03/29/2007 | WO2007035759A1 Modulation of glucocorticoid receptor expression |
| 03/29/2007 | WO2007035757A2 Composition and method for treating iron deficiency anemia |
| 03/29/2007 | WO2007035723A2 Compositions and methods comprising panax species |
| 03/29/2007 | WO2007035722A2 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration |
| 03/29/2007 | WO2007035717A2 Glycolipids and analogues thereof as antigents for nk t cells |
| 03/29/2007 | WO2007035709A2 Novel crystal forms of irinotecan hydrochloride |
| 03/29/2007 | WO2007035703A1 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist |
| 03/29/2007 | WO2007035641A2 Palmarumycin based inhibitors of thioredoxin and methods of using same |
| 03/29/2007 | WO2007035573A2 Anesthesia induction and maintenance drug |
| 03/29/2007 | WO2007035542A1 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| 03/29/2007 | WO2007035496A1 Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| 03/29/2007 | WO2007035489A2 Methods of treating or preventing cancer using pyridine carboxaldehyde pyridine thiosemicarbazone radiosensitizing agents |
| 03/29/2007 | WO2007035478A2 Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| 03/29/2007 | WO2007035430A2 Process for the preparation of benzo [e] [1,2,4] triazepin-2-one derivatives |
| 03/29/2007 | WO2007035428A1 Met kinase inhibitors |
| 03/29/2007 | WO2007035395A2 Therapeutic compositions comprising chorionic gonadotropins and hmg coa reductase inhibitors |
| 03/29/2007 | WO2007035379A1 Polymorphs of tartrate salt of 2-[2-(3-(r)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6h-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor |
| 03/29/2007 | WO2007035372A2 Polymorphs of benzoate salt of 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
| 03/29/2007 | WO2007035368A2 Methods of screening for immuno-adjuvants and vaccines comprising anti-microtubule immuno-adjuvants |
| 03/29/2007 | WO2007035348A2 Nanoparticulate aripiprazole formulations |
| 03/29/2007 | WO2007035322A1 Ryanodine receptor blockers for treating pain |
| 03/29/2007 | WO2007035309A1 Tyrosine kinase inhibitors |
| 03/29/2007 | WO2007035296A2 Polymeric compositions and methods of making and using thereof |
| 03/29/2007 | WO2007035198A2 Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor |
| 03/29/2007 | WO2007035158A1 Alkyl sulfoxide quinolines as nk-3 receptor ligands |
| 03/29/2007 | WO2007035157A1 Alkylnitrile quinolines, as nk-3 receptor ligands |
| 03/29/2007 | WO2007035156A1 N-oxo-heterocycle and n-oxo-alkyl quinoline-4-carboxamides as nk-3 receptor ligands |
| 03/29/2007 | WO2007035154A1 Novel n-pyrazinil-phenylsulfonamide derivatives as chemokine receptor modulators for use in the treatment of asthma |
| 03/29/2007 | WO2007035143A1 Stabilized protease composition |
| 03/29/2007 | WO2007035129A1 Preparation for treating non-infectious inflammatory intestinal diseases |
| 03/29/2007 | WO2007035123A1 Antimutagen |
| 03/29/2007 | WO2007035121A2 Isoflavones for treating mucopolysaccharidoses |
| 03/29/2007 | WO2007035029A1 Pharmaceutical composition for prevention and treatment of drug or alcohol addiction or bipolar disorder using sodium phenylbutyrate |
| 03/29/2007 | WO2007034990A1 Novel combination of drugs as antidepressant |
| 03/29/2007 | WO2007034977A1 METHOD OF ESTIMATING AND IDENTIFYING TARGET mRNA CONTROLLED BY FUNCTIONAL RNA AND METHOD OF USING THE SAME |
| 03/29/2007 | WO2007034927A1 Medicine, food and drink or feed containing sphingomyelin |
| 03/29/2007 | WO2007034924A1 METALLO-β-LACTAMASE INHIBITOR |
| 03/29/2007 | WO2007034917A1 Novel adenine compound |
| 03/29/2007 | WO2007034916A1 Novel adenine compound |
| 03/29/2007 | WO2007034910A1 Medicinal composition for treating bulimia and depression accompanying bulimia |
| 03/29/2007 | WO2007034882A1 Novel adenine compound |
| 03/29/2007 | WO2007034881A1 Novel adenine compound |
| 03/29/2007 | WO2007034852A1 Composition for life extension and method of extending the life |
| 03/29/2007 | WO2007034851A1 Visceral fat accumulation inhibitor |
| 03/29/2007 | WO2007034846A1 Cardiotonic agent comprising grk inhibitor |
| 03/29/2007 | WO2007034817A1 Novel adenine compound |
| 03/29/2007 | WO2007034784A1 Ctgf gene expression inhibitor |
| 03/29/2007 | WO2007034778A1 Prophylactic/therapeutic agent for sleep disorder |